ASRT
Assertio Therapeutics Inc
NASDAQ: ASRT · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$18.43
+2.11% today
Updated 2026-04-30
Market cap
$116.45M
P/E ratio
—
P/S ratio
0.98x
EPS (TTM)
$-4.74
Dividend yield
—
52W range
$9 – $20
Volume
0.2M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
2.0
Growth
F5.0
Quality
C+2.0
Profitability
F7.0
Valuation
B+2/9
Piotroski F-Score
Weak
-2.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$21.33
+15.74%
12-Month target
—
—
Intrinsic (DCF)
$78.89
Margin of safety
+84.85%
1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 84.85% below intrinsic value
+ Debt/equity 0.37x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -2.28 — distress zone
- Thin margins at -25.60%
- Negative free cash flow $-29.97M
- Revenue declining -57.90% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $156.23M | $152.07M | $124.96M | $118.71M | $118.71M |
| Net income | $109.63M | $-331.94M | $-21.58M | $-29.50M | $-11.06M |
| EPS | — | — | — | — | $-4.74 |
| Free cash flow | $78.32M | $48.98M | $26.41M | $-28.18M | $-29.97M |
| Profit margin | 70.17% | -218.28% | -17.27% | -24.85% | -25.60% |
Peer comparison
Smart narrative
Assertio Therapeutics Inc trades at $18.43. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -2.28, it sits in the distress. TTM revenue stands at $118.71M. with profit margins at -25.60%. Our DCF model estimates intrinsic value at $78.89.
Frequently asked questions
What is Assertio Therapeutics Inc's stock price?
Assertio Therapeutics Inc (ASRT) trades at $18.43.
Is Assertio Therapeutics Inc overvalued?
Smart Value Score 35/100 (Grade D, Sell). DCF value $78.89.
What is the price target of Assertio Therapeutics Inc (ASRT)?
The analyst target price is $21.33, representing +15.7% upside from the current price of $18.43.
What is the intrinsic value of Assertio Therapeutics Inc (ASRT)?
Based on our DCF model, intrinsic value is $78.89, a +84.8% margin of safety versus $18.43.
What is Assertio Therapeutics Inc's revenue?
TTM revenue is $118.71M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-2.28 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.98x
ROE-28.20%
Beta0.43
50D MA$15.03
200D MA$12.47
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—